- Trials with a EudraCT protocol (71)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
71 result(s) found for: Pulmonary tuberculosis.
Displaying page 1 of 4.
EudraCT Number: 2005-003562-42 | Sponsor Protocol Number: AdjuVIT v3 | Start Date*: 2006-09-27 | |||||||||||
Sponsor Name:Queen Mary, University of London | |||||||||||||
Full Title: Trial of Adjunctive Vitamin D in Tuberculosis Treatment (AdjuVIT) | |||||||||||||
Medical condition: Pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001929-40 | Sponsor Protocol Number: AZT_DSTB_BB | Start Date*: 2017-11-21 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis | |||||||||||||
Medical condition: Pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002514-40 | Sponsor Protocol Number: CISTA-TB | Start Date*: 2019-10-31 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis d... | |||||||||||||
Medical condition: Pulmonary Mycobacterium tuberculosis infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003633-24 | Sponsor Protocol Number: UITB-Study-29 | Start Date*: 2009-01-08 | |||||||||||
Sponsor Name:TB Investigation Unit of Barcelona | |||||||||||||
Full Title: Evaluation of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis Evaluación de una Pauta con Rifapentina para la Fase Intensiva del tratamiento de la Tub... | |||||||||||||
Medical condition: To compare two treatments for Pulmonary Tuberculosis Comparar dos tratamientos para la tuberculosis pulmonar | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000224-41 | Sponsor Protocol Number: IDANAT2 | Start Date*: 2008-08-26 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransfe... | |||||||||||||
Medical condition: pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005229-31 | Sponsor Protocol Number: 242-07-204 | Start Date*: 2008-02-14 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc. | |||||||||||||
Full Title: A Multi center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC-67683 in Patients with Pulmonary Sputum Cu... | |||||||||||||
Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004295-18 | Sponsor Protocol Number: DRTB-HDT | Start Date*: 2022-11-21 | |||||||||||
Sponsor Name:The Aurum Institute | |||||||||||||
Full Title: A randomized controlled trial of two adjunctive host-directed therapies in rifampin-resistant tuberculosis (DRTB-HDT) | |||||||||||||
Medical condition: Rifampin-resistant pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022271-59 | Sponsor Protocol Number: 242-09-213 | Start Date*: 2011-07-19 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dos... | |||||||||||||
Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014944-13 | Sponsor Protocol Number: 242-08-210 | Start Date*: 2009-11-06 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 2, Multi-center, Non-controlled, Open-label Dose Escalation Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Orally Administered OPC-67683 Two Times Daily to Pati... | |||||||||||||
Medical condition: Pulmonary Multidrug-resistant Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005107-26 | Sponsor Protocol Number: 242-07-208 | Start Date*: 2009-04-08 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc. | |||||||||||||
Full Title: A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up t... | |||||||||||||
Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002202-30 | Sponsor Protocol Number: R207910BAC2001 | Start Date*: 2004-10-18 |
Sponsor Name:Tibotec Pharmaceuticals Ltd. | ||
Full Title: An open label study to evaluate the effects on Mycobacterium tuberculosis, safety, tolerability and pharmacokinetics of single doses of R207910, in treatment naive patients with mycobacterium tuber... | ||
Medical condition: Tuberculosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000632-27 | Sponsor Protocol Number: PORT-01 | Start Date*: 2022-08-03 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients | ||
Medical condition: Tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000653-23 | Sponsor Protocol Number: TMC207-TiDP13-C210 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Myc... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008444-25 | Sponsor Protocol Number: TMC207-TiDP13-C209 | Start Date*: 2009-06-04 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: A Phase II, open-label trial with TMC207 as part of a multi-drug resistant tuberculosis (MDR-TB) treatment regimen in subjects with sputum smear-positive pulmonary infection with MDR-TB. | |||||||||||||
Medical condition: Sputum smear-positive pulmonary multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021125-12 | Sponsor Protocol Number: TMC207TBC3001 | Start Date*: 2011-09-16 | |||||||||||
Sponsor Name:Janssen Infectious Diseases BVBA | |||||||||||||
Full Title: Early access of TMC207 in combination with other anti-tuberculosis (TB) drugs in subjects with extensively drug resistant (XDR) or pre-XDR pulmonary TB | |||||||||||||
Medical condition: Tuberculosis (TB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003372-23 | Sponsor Protocol Number: TMC207-C211 | Start Date*: 2015-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antimycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004462-40 | Sponsor Protocol Number: TMC207-TiDP13-C208 | Start Date*: 2007-12-20 | |||||||||||
Sponsor Name:Tibotec BVBA | |||||||||||||
Full Title: A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection... | |||||||||||||
Medical condition: Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003301-22 | Sponsor Protocol Number: AC-R6 | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:Archivel Farma S.L. | |||||||||||||
Full Title: A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTI® immunotherapy with the standard treatment in patients with TB (CONSTAN) | |||||||||||||
Medical condition: Pulmonary Tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005617-36 | Sponsor Protocol Number: TESEC-06 | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:Statens Serum Institut | |||||||||||||
Full Title: A phase III contact tracing trial comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomized split body safety assessment of C-Tb ve... | |||||||||||||
Medical condition: Tuberculosis diagnostic tool | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003146-36 | Sponsor Protocol Number: RIAlta-1 | Start Date*: 2023-11-15 |
Sponsor Name:Vall d'Hebron Research Institute (VHIR) | ||
Full Title: Safety of Rifampicin at High Dose for the Treatment of Adult Subjects with Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis | ||
Medical condition: Pulmonary and extrapulmonary tuberculosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) ES (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
